Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
28 hedge funds and large institutions have $3.16M invested in Intellipharmaceuticals International Inc. in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.
173% more capital invested
Capital invested by funds: $1.16M → $3.16M (+$2M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
17% more funds holding
Funds holding: 24 → 28 (+4)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
85% less call options, than puts
Call options by funds: $11K | Put options by funds: $71K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.76M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$984K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$28.9K |
| 4 |
VF
Virtu Financial
New York
|
+$25.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$134K |
| 2 |
FFA
First Foundation Advisors
Irvine,
California
|
-$96.1K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$52K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$15.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| – | -$7K | -727 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | -$908 | -100 | -97% |
|
28
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$182 | +20 | New |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | +$273 | +30 | +150% |
|
IPCI Hedge Fund Activity: Q4 2017 in Review
28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q4 2017, worth a combined $3.16M — up 173% from $1.16M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IPCI positions and 5 closed out — a net gain of 4 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.76M. The largest seller was Bank of Montreal, cutting an estimated $134K.
- 28 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q4 2017, up from 24 in Q3 2017.
- Funds reported $3.16M of Intellipharmaceuticals International Inc. stock for Q4 2017, up 173% quarter-over-quarter.
- 9 funds opened new Intellipharmaceuticals International Inc. positions in Q4 2017 and 5 closed out, a net change of +4 holders.
- The largest Intellipharmaceuticals International Inc. buyer in Q4 2017 was Armistice Capital, an estimated $1.76M added.
- The largest Intellipharmaceuticals International Inc. seller in Q4 2017 was Bank of Montreal, an estimated $134K sold.
Based on aggregated 13F filings for Q4 2017.